An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.
FEMETRIC RECORD · PUBLICPemvidutide
Weight ManagementFat LossBody Composition
Status
Clinical Development
Related
3
Sources
1
UPDATED 2026-09-13
01
Protocol references
SOURCE-LINKED
PUBLISHED STUDY
Source-linked research context
No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.
Route
Subcutaneous
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
PUBLISHED STUDYClinicalTrials.gov, 2024Verified 2026-09-13
Pemvidutide is designed to engage GLP-1 and glucagon receptors. Published and sponsor-reported findings are labeled separately as the program develops.
Mechanism summaries are stored with field-level source provenance for editorial audit.
07
Related research goals
08
Related peptides
01PEPTIDE
Survodutide
An investigational GLP-1 and glucagon receptor dual agonist in clinical development for obesity and metabolic liver disease.
Weight ManagementAppetiteFat Loss
02PEPTIDE
Mazdutide
A GLP-1 and glucagon receptor dual agonist studied in obesity and type 2 diabetes, with development and regulatory status varying by region.
Weight ManagementGlucose / InsulinFat Loss
03PEPTIDE
Retatrutide
An investigational GIP, GLP-1 and glucagon receptor agonist studied for obesity and metabolic outcomes.